SEC Form 4 · accession 0001140361-18-027571
KalVista Pharmaceuticals, Inc. · KALV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Yea
Officer — Chief Development Officer
Period of report
Jun 4, 2018
Accepted (ET)
Jun 6, 2018 · 5:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348911
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $8.21 | Jun 4, 2018 | A | 53,500 | A | — | Jun 3, 2028 | Common Stock | 53,500 | 53,500 | D |
Explanation of responses
- F1The option vests over a 4 year period: 1/48th on July 4, 2018, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.